John Baker reviews a recent participant-level meta-analysis of six placebo-controlled studies, which looks at the initial severity of schizophrenia and the efficacy of antipsychotics including Olanzapine, Risperidone and Amisulpride.
[read the full story...]
In her debut blog, Nicola Coop summarises a recent meta-analysis looking at the use of antidepressants, antipsychotics and hormonal therapy for people with anorexia nervosa.
[read the full story...]
Joe Judge reviews a recent meta-analysis of placebos in antipsychotic trials, which finds that the placebo response has increased significantly in the last 50 years.
[read the full story...]
Josephine Neale reports on a recent cohort study that finds less than half of UK prescriptions for antipsychotics are issued for main licensed conditions (e.g. psychosis or bipolar disorder). The research provides a reminder about the dangers of prescribing antipsychotics to people with dementia.
[read the full story...]
Andrew Jones summarises a large Finnish population-based cohort study, which finds that childhood adversities strongly predict the use of psychotropic drugs (such as antidepressants and antipsychotics) in adulthood.
[read the full story...]
Elena Marcus summarises a recent network meta-analysis published in The Lancet of the comparative efficacy and tolerability of medication for the maintenance treatment of bipolar disorder.
[read the full story...]
Keith Laws, Alex Langford and Samei Huda provide a critique of the British Psychological Society Division of Clinical Psychology report published today.
[read the full story...]
1 in 100 adults experience autism worldwide but little research exists on autism in adults. Adults with autism and learning disability may have distinct needs, and in particular challenging behaviour, which may increase their social isolation and reduce access to quality health care.
In her debut blog, Kate van Dooren looks at a systematic review from Canadian researchers who examined the evidence for the use of medications for challenging behaviours in adults with autism and learning disability.
[read the full story...]
Laurence Palfreyman summarises 3 recent Cochrane reviews, which investigate high-potency versus low-potency first-generation antipsychotic drugs for schizophrenia. The reviews find little difference in efficacy between the high-potency antipsychotics Trifluoperazine, Haloperidol, Fluphenazine, and low-potency typical antipsychotics.
[read the full story...]
André Tomlin summarises the second National Audit of Schizophrenia, which highlights that many people with schizophrenia are still not getting the high quality psychological and medical treatment they deserve.
[read the full story...]
